Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more
Immunitybio Inc (IBRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 1.356x
Based on the latest financial reports, Immunitybio Inc (IBRX) has a cash flow conversion efficiency ratio of 1.356x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.91 Million) by net assets ($-50.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunitybio Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Immunitybio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Immunitybio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunitybio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marui Group Co. Ltd
F:MUI
|
N/A |
|
La Française des Jeux Société anonyme
VI:FDJ
|
N/A |
|
Sandfire Resources Limited
PINK:SNDFY
|
N/A |
|
Four Corners Property Trust Inc
NYSE:FCPT
|
0.029x |
|
Zhejiang CFMoto Power Co Ltd
SHG:603129
|
0.109x |
|
Scotts Miracle-Gro Company
NYSE:SMG
|
-0.487x |
|
HMT(Xiamen)New Technical
SHG:603306
|
0.018x |
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
0.027x |
Annual Cash Flow Conversion Efficiency for Immunitybio Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Immunitybio Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-488.13 Million | $-391.24 Million | 0.802x | +28.05% |
| 2023-12-31 | $-585.94 Million | $-366.76 Million | 0.626x | -16.58% |
| 2022-12-31 | $-449.82 Million | $-337.51 Million | 0.750x | -33.31% |
| 2021-12-31 | $-243.91 Million | $-274.42 Million | 1.125x | -22.37% |
| 2020-12-31 | $-118.49 Million | $-171.72 Million | 1.449x | +214.98% |
| 2019-12-31 | $120.68 Million | $-152.11 Million | -1.260x | -190.36% |
| 2018-12-31 | $146.01 Million | $-63.38 Million | -0.434x | -94.75% |
| 2017-12-31 | $218.84 Million | $-48.78 Million | -0.223x | -69.47% |
| 2016-12-31 | $293.42 Million | $-38.59 Million | -0.132x | -85.04% |
| 2015-12-31 | $356.00 Million | $-25.30 Million | -0.071x | +22.43% |
| 2014-12-31 | $58.42 Million | $-5.35 Million | -0.092x | -139.72% |
| 2013-12-31 | $-2.90 Million | $-668.00K | 0.231x | -- |